Skyline Therapeutics

Skyline Therapeutics is an innovation-driven gene therapy company at the clinical stage, dedicated to developing unique and novel solutions to address unmet needs in rare and severe diseases. Our advanced adeno-associated virus (AAV) platform encompasses a range of proprietary technologies for capsid discovery, transgene design, and vector engineering. By combining our AAV expertise with robust in-house process and analytical development, as well as GMP production for clinical-grade plasmids and viral vectors, we are advancing a diversified pipeline of gene therapies targeting ocular, neurological, cardiovascular, and metabolic diseases.